DU PONT MERCK's ANTIPARKINSONIAN AGENT SINEMET CR IS "APPROVABLE"
Executive Summary
Du Pont Merck's Sinemet CR received "approvable" status on Nov. 27 (see NDA list below). The company said it expects approval of the new sustained-release formulation of the antiparkinsonian agent (carbidopa 50 mg/levodopa 200 mg tablets) "any day now." The sustained-release formulation has been under development for 10 years and a full NDA was filed in April 1988. Du Pont Merck said it will continue to market the standard formulation of Sinemet since some patients require both formulations for treatment. Chart omitted.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth